* During this congress, PharmaMar will inform in an oral session the results of its Phase II clinical trial with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer .* A prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma(T-SAR trial) will be presented in an oral session by the French Sarcoma Group .
PharmaMar (MCE:PHM) will present the data obtained from various clinical trials carried out with its antitumoral compounds of marine origin: Yondelis® (trabectedin) and lurbinectedin (PM1183), at the European Society of Medical Oncology (ESMO) congress that will take place in Copenhagen (Denmark), from the 7th to the 11th of October.
During this congress, PharmaMar will participate at different posters sessions and/or oral presentations the latest clinical advances of these molecules. In this edition, PharmaMar will present, among others, the results of a single-agent (lurbinectedin) Phase II trial in patients with BRCA 1/2 -associated metastatic breast cancer. Moreover, the French Sarcoma Group will introduce the data from a Phase III prospective study carried out in France (T-SAR), which compares trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma (ASTS).
"At this year's edition of ESMO, we will announce the latest breakthroughs obtained with lurbinectedin in different tumor types. Through the various clinical trials that PharmaMar has running, we can observe that PM1883 is effective in combination and also as single-agent. This allows us to think that we have a great molecule for the treatment of different types of solid tumors, such as breast and endometrial cancers, amongst others", as Dr. Arturo Soto, director of Clinical Development at PharmaMar´s Oncology Business Unit, explains.